Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May;28(5):504-510.
doi: 10.5005/jp-journals-10071-24707.

Survey of Pediatric Status Epilepticus Treatment Practices and Adherence to Management Guidelines (Pedi-SPECTRUM e-Survey)

Renu Suthar  1 , Suresh Kumar Angurana  2 , Karthi Nallasamy  2 , Arun Bansal  2 , Jayashree Muralidharan  2
Affiliations
Case Reports

Survey of Pediatric Status Epilepticus Treatment Practices and Adherence to Management Guidelines (Pedi-SPECTRUM e-Survey)

Renu Suthar et al. Indian J Crit Care Med. 2024 May.

Abstract

Aim: Survey of treatment practices and adherence to pediatric status epilepticus (PSE) management guidelines in India.

Methods: This eSurvey was conducted over 35 days (15th October to 20th November 2023) and included questions related to hospital setting; antiseizure medications (ASMs); ancillary treatment; facilities available; etiology; and adherence to PSE management guidelines.

Results: A total of 170 respondents participated, majority of them were working in tertiary level hospitals (94.1%) as pediatric intensivists (56.5%) and pediatricians (19.4%), and were in clinical practice for 2-10 years (46.5%). Majority use intravenous (IV) midazolam and levetiracetam as first- and second-line ASMs (67.1 and 51.2%, respectively). In cases with refractory status epilepticus (RSE), the most commonly used ASM is midazolam infusion (92.4%). For super-refractory status epilepticus (SRSE), the commonly used third-line ASMs include midazolam infusion (34.1%), thiopentone infusion (26.5%), high dose phenobarbitone (18.2%), and ketamine infusion (15.3%). Overall, in cases with SRSE, 44.7% respondents use ketamine infusion, 42.5% use add-on oral topiramate, and 34.7% use high-dose phenobarbitone (1-3 mg/kg/hour) infusion. Most respondents targeted both clinical and EEG seizure control (48.8%). Ancillary treatment used for SRSE included IV pyridoxine (57.1%), methylprednisolone (45.3%), IVIG (42.4%), ketogenic diet (40.6%), and second-line immunomodulation (33.5%). Most common causes were febrile SE, viral encephalitis, and febrile illness-related epilepsy syndrome (60.6%, 52.4%, and 37.1%, respectively). Facilities available included pediatric intensive care units (PICU) (97.1%), mechanical ventilation (98.2%), pediatric neurologist (68.8%), MRI brain (86.5%), EEG (69.4%), and viral PCR (58.2%). The compliance with guidelines for timing of initiation of ASM ranged from 63.5 to 88.8%.

Conclusion: Intravenous midazolam bolus/es, levetiracetam, and midazolam infusion are commonly used first-, second-, and third-line ASMs, respectively. There were wide variations in use of ASMs for RSE and SRSE, ancillary treatment, and compliance to PSE management guidelines.

How to cite this article: Suthar R, Angurana SK, Nallasamy K, Bansal A, Muralidharan J. Survey of Pediatric Status Epilepticus Treatment Practices and Adherence to Management Guidelines (Pedi-SPECTRUM e-Survey). Indian J Crit Care Med 2024;28(5):504-510.

Keywords: Antiseizure medications; Midazolam; Nonconvulsive status epilepticus; Status epilepticus; Thiopentone.

PubMed Disclaimer

Conflict of interest statement

Source of support: Nil Conflict of interest: None

Figures

Fig. 1
Fig. 1
Bar diagram showing number of respondents from different states and union territories
Fig. 2
Fig. 2
Bar diagram showing common diagnosis of pediatric status epilepticus as reported by the respondents
See this image and copyright information in PMC

References

    1. Chin RFM. The outcomes of childhood convulsive status epilepticus. Epilepsy Behav. 2019;101(Pt B):106286. doi: 10.1016/j.yebeh.2019.04.039. - DOI - PubMed
    1. Kling R, Ritvanen J, Mustonen H, Kämppi L. Long-term outcome of convulsive status epilepticus: A 10-year follow-up. Epileptic Disord. 2022;24(6):1046–1059. doi: 10.1684/epd.2022.1482. English. - DOI - PubMed
    1. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61. doi: 10.5698/1535-7597-16.1.48. - DOI - PMC - PubMed
    1. Van de Voorde P, Turner NM, Djakow J, de Lucas N, Martinez-Mejias A, Biarent D, et al. European Resuscitation Council Guidelines 2021: Paediatric life support. Resuscitation. 2021;161:327–387. doi: 10.1016/j.resuscitation.2021.02.015. - DOI - PubMed
    1. Mishra D, Sharma S, Sankhyan N, Konanki R, Kamate M, Kanhere S, et al. Multi-disciplinary group on management of status epilepticus in children in India. Consensus guidelines on management of childhood convulsive status epilepticus. Indian Pediatr. 2014;51(12):975–990. doi: 10.1007/s13312-014-0543-4. - DOI - PubMed

Publication types

LinkOut - more resources